Skyrizi (Risankizumab-rzaa)
Drug Class: Biologic Immunosuppressant (IL-23 Inhibitor)
Biologic medication that selectively inhibits interleukin-23 (IL-23), used to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease by targeting specific immune pathways.
Common Side Effects of Skyrizi
- Upper respiratory infections
- Headache
- Fatigue
- Injection site reactions
- Fungal infections
- TB reactivation risk